@FiercePharma: Novartis goes '80s with Cyndi Lauper-led psoriasis campaign. FiercePharmaMarketing story | Follow @FiercePharma
@EricPFierce: ICYMI last week: Aprecia is building $25M plant where it will do 3D printing of drugs. Article | Follow @EricPFierce
@CarlyHFierce: ICYMI Friday: Orexigen picks up new trial tab to settle Contrave dispute with partner Takeda. More | Follow @CarlyHFierce
> Pharma deals, including AbbVie's ($ABBV) deal for Pharmacyclics and Valeant's ($VRX) buyout of Salix Pharmaceuticals, are boosting returns at hedge funds betting on M&A. Report
> The market for Fabry Disease drugs will mushroom to $1.25 billion by 2024 from $683 million last year as awareness and diagnosis improve, GlobalData says. Report
> At-risk patients say they are having trouble persuading their doctors to prescribe Gilead Sciences' ($GILD) Truvada as a preventive against HIV, despite the FDA's approval for that use. Report
> A new Senate bill expanding protection for whistleblowers could make life more difficult for pharma companies looking to comply with antitrust laws. Report
Medical Device News
@FierceMedDev: UPDATED with interview of CEO: TAVR maker JenaValve receives $26.5M to fund U.S. studies. Report | Follow @FierceMedDev
@VarunSaxena2: Crowdsourcing challenge winner looking to commercialize NIH tech to diagnose brain cancer. Article | Follow @VarunSaxena2
@EmilyWFierce: Congress urges feds to probe FDA over morcellator safety concerns. More | Follow @EmilyWFierce
> Bill introduced to fix FDA's combination product regs; attorneys say it doesn't go far enough. Story
> Sisu to put emergency blood recycling device through trials later this year. Article
Biotech News
@FierceBiotech: AstraZeneca offers $727M package to partner with Inovio on immuno-oncology. News | Follow @FierceBiotech
@JohnCFierce: Sanofi takes another stab at cancer with Evotec, Apeiron checkpoint partnership. Article | Follow @JohnCFierce
@DamianFierce: Like most people, I'm waiting for Thug_BioAnalyst to weigh in before I form an opinion on anything this morning. | Follow @DamianFierce
> Karyopharm tanks as sepsis scares plague its cancer contender. Article
> Sorrento's biotech buyouts bag CAR-T drugs. Item
> Gates backs a $120M breakout round for CRISPR/Cas9 pioneers at Editas. Story
Animal Health News
> Aratana continues to trim losses in Q2 as it focuses on animal treatments. News
> Merck to partner with National Milk Producers group on training and animal care. Report
> USDA grants conditional license to Zoetis for canine anti-itch therapy. Story
> Feds indict four with smuggling bogus pet products into the U.S. Item
> Dechra to buy control of Croatian animal vaccine maker for $56.4M. Article
Biotech IT News
> Apple's ResearchKit goes global as heart study expands into Hong Kong and U.K. Item
> IBM makes $1B bid for Merge to bolster Watson's image analytics capabilities. Report
> Teva buys majority stake in Immuneering to access genome analysis tools. More
> Illumina strikes deal to buy LIMS provider GenoLogics. Article
> FDA makes its first approval of a 3D-printed drug. Story
Pharma Marketing News
> Allergan plots Namzaric DTC campaign to shore up its Namenda defenses. Item
> Amarin case could unleash a flood of off-label promos. Report
> Novartis goes '80s with Cyndi Lauper-led psoriasis campaign. More
> Xtandi marketer Astellas scrums with rugby partners for prostate cancer awareness. Story
> Big Pharma feeds controversy by routing big bucks to private CME. Article
And Finally... Amid consumer worries over their safety, Johnson & Johnson ($JNJ) and Colgate/Palmolive are phasing out microbeads from their personal care products. Report